264 related articles for article (PubMed ID: 12183434)
1. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor.
Shen WH; Zhou JH; Broussard SR; Freund GG; Dantzer R; Kelley KW
Cancer Res; 2002 Aug; 62(16):4746-56. PubMed ID: 12183434
[TBL] [Abstract][Full Text] [Related]
2. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
3. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.
Oesterreich S; Zhang P; Guler RL; Sun X; Curran EM; Welshons WV; Osborne CK; Lee AV
Cancer Res; 2001 Aug; 61(15):5771-7. PubMed ID: 11479214
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells.
Guvakova MA; Surmacz E
Exp Cell Res; 1997 Feb; 231(1):149-62. PubMed ID: 9056422
[TBL] [Abstract][Full Text] [Related]
5. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
[TBL] [Abstract][Full Text] [Related]
7. Ethanol inhibits insulin-like growth factor-1-mediated signalling and proliferation of C6 rat glioblastoma cells.
Resnicoff M; Rubini M; Baserga R; Rubin R
Lab Invest; 1994 Nov; 71(5):657-62. PubMed ID: 7526037
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
9. An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer.
Mamay CL; Mingo-Sion AM; Wolf DM; Molina MD; Van Den Berg CL
Oncogene; 2003 Jan; 22(4):602-14. PubMed ID: 12555073
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
Varma H; Conrad SE
Cancer Res; 2002 Jul; 62(14):3985-91. PubMed ID: 12124331
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6.
Lazarus DD; Moldawer LL; Lowry SF
Lymphokine Cytokine Res; 1993 Aug; 12(4):219-23. PubMed ID: 8218594
[TBL] [Abstract][Full Text] [Related]
13. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines.
Jackson JG; Zhang X; Yoneda T; Yee D
Oncogene; 2001 Nov; 20(50):7318-25. PubMed ID: 11704861
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
[TBL] [Abstract][Full Text] [Related]
15. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro.
Danforth DN; Sgagias MK
Cancer Res; 1993 Apr; 53(7):1538-45. PubMed ID: 8453620
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.
Cui X; Kim HJ; Kuiatse I; Kim H; Brown PH; Lee AV
Cancer Res; 2006 May; 66(10):5304-13. PubMed ID: 16707456
[TBL] [Abstract][Full Text] [Related]
18. Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death.
Wu Y; Tewari M; Cui S; Rubin R
J Cell Physiol; 1996 Sep; 168(3):499-509. PubMed ID: 8816904
[TBL] [Abstract][Full Text] [Related]
19. Beneficial synergistic interactions of TNF-alpha and IL-6 in C2 skeletal myoblasts--potential cross-talk with IGF system.
Al-Shanti N; Saini A; Faulkner SH; Stewart CE
Growth Factors; 2008 Apr; 26(2):61-73. PubMed ID: 18428025
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
